Tag Archives: Prix Galien

Russian Innovation: A Higher Mark

The pursuit of excellence in biopharmaceutical innovation in Russia has never had a sponsor—until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an October 24 awards dinner to recognize the best in new drug research as […]
Posted in E-Media, Events, R&D, Strategy | Also tagged , , , , , , , | Leave a comment

CEOs Sound Out on Health Reform: Stop Swinging from the Fence

At last week’s  4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.  The centerpiece of the day was a panel on  US health reform – focused on rollout of the  Affordable Care Act — featuring […]
Posted in Events, leadership, People, R&D, Regulatory | Also tagged , , , , , , , , , , , | Leave a comment

Ethics in Drug Innovation: The First Hurdle is Trust

By Ansis Helmanis Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry.  This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel […]
Posted in Europe, Events, FDA, Global, Guest Blog, healthcare, leadership, Market Access, Patient Communication, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

Prix Galien Winners Embody Innovation

The winners of the fifth annual Prix Galien USA represent the progress of the entire industry and show us how far we’ve come in advancing the pace of innovation and commercializing new medicines that save lives and improve standard of care. Pharmaceutical Executive served as a lead media partner for the 2011 Prix Galien awards, […]
Posted in Events | Also tagged , | Leave a comment

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, leadership, Market Access, pricing, R&D, Strategy | Also tagged , , , | Leave a comment
  • Categories

  • Meta